SCHEMBL1123583

SCHEMBL1123583

Cc1ccc(N2CCN(c3cc(N4CCOCC4)nc(N4CCOCC4)n3)CC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.65
NPSR1 Q6W5P4 1/20 0.61
HRH4 Q9H3N8 1/20 0.61
LMNA P02545 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
MAPT P10636 3/20 0.52
L3MBTL1 Q9Y468 4/20 0.51
KDM4E B2RXH2 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
AKR1C3 P42330 1/20 0.50
GBA1 P04062 1/20 0.49
HPGD P15428 1/20 0.48
PIK3CB P42338 1/20 0.48
PIK3CA P42336 2/20 0.48
ATM Q13315 1/20 0.48
MEN1 O00255 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1123990 1.00 KMT2A (0.65) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1124097 0.85 MTOR (0.61) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1123884 0.85 MAPT (0.57) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1123861 0.85 KMT2A (0.59) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1123904 0.85 KMT2A (0.59) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1124300 0.84 HTT (0.62) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1123979 0.84 HTT (0.62) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1123614 0.84 HTT (0.62) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL9003193 0.83 KMT2A (0.76) KMT2ANPSR1HRH4LMNASMN1; SMN2
SCHEMBL1124031 0.82 PTGS2 (0.58) KMT2ANPSR1HRH4SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US claimed
EP-2284160-A1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-02-16 EP claimed
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US disclosed
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US disclosed
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US disclosed
EP-2284160-B1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KK (JP) 2013-05-15 EP disclosed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US disclosed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US disclosed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US disclosed
EP-2284160-A1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF CASP3, DPYD, CASP1 KMT2A 4422/4885NPSR1 2137/4885HRH4 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.